Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.
Animals
Chelating Agents
/ chemistry
Female
Fluorescence
Gallium Radioisotopes
/ pharmacokinetics
Humans
Mice
Mice, Nude
Neuroendocrine Tumors
/ diagnostic imaging
Pancreatic Neoplasms
/ diagnostic imaging
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
/ pharmacokinetics
Receptors, Somatostatin
/ antagonists & inhibitors
Surgery, Computer-Assisted
/ methods
Tissue Distribution
Tumor Cells, Cultured
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 07 2019
15 07 2019
Historique:
received:
09
10
2018
revised:
11
03
2019
accepted:
18
04
2019
pubmed:
25
4
2019
medline:
23
9
2020
entrez:
25
4
2019
Statut:
ppublish
Résumé
Clinically available intraoperative imaging tools to assist surgeons in identifying occult lesions are limited and partially responsible for the high rate of disease recurrence in patients with neuroendocrine tumors (NET). Using the established clinical efficacy of radiolabeled somatostatin analogs as a model, we demonstrate the ability of a fluorescent somatostatin analog to selectively target tumors that overexpress somatostatin receptor subtype-2 (SSTR2) and demonstrate utility for fluorescence-guided surgery (FGS). A multimodality chelator (MMC) was used as a "radioactive linker" to synthesize the fluorescently labeled somatostatin analog, Direct labeling with The radioactive utility of the MMC allowed us to validate the binding properties of a novel FGS agent that could have a broad impact on cancer outcomes by equipping surgeons with real-time intraoperative imaging capabilities.
Identifiants
pubmed: 31015345
pii: 1078-0432.CCR-18-3312
doi: 10.1158/1078-0432.CCR-18-3312
pmc: PMC6675459
mid: NIHMS1527775
doi:
Substances chimiques
Chelating Agents
0
Gallium Radioisotopes
0
Radiopharmaceuticals
0
Receptors, Somatostatin
0
SSTR2 protein, human
0
Gallium-67
4LJK511Z86
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4332-4342Subventions
Organisme : NCI NIH HHS
ID : K99 CA218875
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB017279
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Eur J Nucl Med. 2001 Dec;28(12):1751-7
pubmed: 11734911
Ann Surg. 2004 Jul;240(1):117-22
pubmed: 15213627
Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):724
pubmed: 15551131
Cancer Biother Radiopharm. 2005 Apr;20(2):231-6
pubmed: 15869461
Q J Nucl Med Mol Imaging. 2005 Sep;49(3):237-44
pubmed: 16172569
Eur J Nucl Med Mol Imaging. 2006 May;33(5):532-40
pubmed: 16491425
Nucl Med Commun. 2007 May;28(5):359-63
pubmed: 17414885
Nucl Med Biol. 2008 Aug;35(6):673-8
pubmed: 18678352
Ann Surg Oncol. 2010 Apr;17(4):1094-100
pubmed: 20033320
Ann Surg Oncol. 2010 Dec;17(12):3129-36
pubmed: 20585879
Bioconjug Chem. 2010 Oct 20;21(10):1709-19
pubmed: 20812730
J Nucl Med. 2011 Jan;52(1):123-31
pubmed: 21149478
Prostate. 2012 Feb 1;72(2):129-46
pubmed: 21538422
J Drug Target. 2011 Sep;19(8):719-30
pubmed: 21830941
Nat Med. 2011 Sep 18;17(10):1315-9
pubmed: 21926976
Mol Imaging Biol. 2012 Jun;14(3):261-76
pubmed: 22160875
Clin Nucl Med. 2012 Feb;37(2):142-7
pubmed: 22228336
Oncologist. 2013;18(5):525-32
pubmed: 23615698
Trends Pharmacol Sci. 2013 Dec;34(12):676-88
pubmed: 24183675
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):25-32
pubmed: 25125202
Ann Surg Oncol. 2015 Mar;22(3):1000-7
pubmed: 25190116
Clin Cancer Res. 2015 Aug 15;21(16):3658-66
pubmed: 25904751
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S676-82
pubmed: 26350374
J Nucl Med. 2016 Jan;57(1):144-50
pubmed: 26449839
Clin Cancer Res. 2016 Mar 15;22(6):1403-12
pubmed: 26490315
J Nucl Med. 2016 Aug;57(8):1289-95
pubmed: 27127222
Clin Cancer Res. 2016 Jun 15;22(12):2929-38
pubmed: 27306792
Nat Rev Clin Oncol. 2017 Jun;14(6):347-364
pubmed: 28094261
Clin Cancer Res. 2017 Jun 1;23(11):2730-2741
pubmed: 28119364
Cancer Res. 2017 May 1;77(9):2197-2206
pubmed: 28428283
Clin Cancer Res. 2017 Aug 15;23(16):4744-4752
pubmed: 28446503
J Nucl Med. 2017 Nov;58(11):1858-1864
pubmed: 28572490
ACS Med Chem Lett. 2017 Jun 06;8(7):720-725
pubmed: 28740605
Bioconjug Chem. 2017 Nov 15;28(11):2865-2873
pubmed: 28945346
Surgery. 2018 Jan;163(1):218-225
pubmed: 29103583
Pancreas. 2018 Jan;47(1):130-133
pubmed: 29232342
Front Oncol. 2017 Dec 22;7:314
pubmed: 29312886
Ann Thorac Surg. 2018 Mar;105(3):901-908
pubmed: 29397932
Ann Surg Oncol. 2018 Jul;25(7):1880-1888
pubmed: 29667116
Cancer Res. 2018 Sep 1;78(17):5144-5154
pubmed: 29967260
Ann Thorac Surg. 2019 Jan;107(1):224-232
pubmed: 30028985
Endocr Rev. 1995 Aug;16(4):427-42
pubmed: 8521788
Jpn J Cancer Res. 1996 Sep;87(9):995-1000
pubmed: 8878464